Is Vidicitomab (Aidexi) an immune drug or a targeted drug and its mechanism of action?

Vedisitomab (Disitamab) is a targeted drug that belongs to the category of antibody drug conjugates (ADC). It mainly targets tumor cells with overexpressed HER2 receptors. It uses monoclonal antibodies to specifically recognize HER2 receptors and deliver cytotoxic drugs directly to cancer cells to achieve precise killing while minimizing damage to normal cells. This characteristic distinguishes vedicitomab from traditional chemotherapy drugs and from generalized immunomodulatory drugs.

Its mechanism of action includes two key links: First, the anti-HER2 monoclonal antibody part specifically binds to the HER2 receptor on the surface of tumor cells, mediating antibody-dependent cytotoxicity and receptor endocytosis; second, the coupled cytotoxin is released in the tumor cells, directly interfering with the DNA or microtubule structure, leading to tumor cell apoptosis. This targeted delivery mode not only ensures anti-tumor accuracy, but also reduces the incidence of systemic toxic side effects.

In clinical application, vedicitomab is mainly used for HER2 patients with positive breast cancer, gastric cancer and some bladder cancer. Studies have shown that the drug can effectively shrink tumors and extend progression-free survival in advanced or metastatic patients, and achieve significant efficacy in some refractory patients. Its advantages of precise targeting and cytotoxic delivery make it an important choice in the field of targeted therapy.

Generally speaking, Disitamab (Disitamab) is a targeted drug rather than a simple immunomodulatory drug. Through the dual mechanism of antibody recognition and drug conjugation, efficient killing and precise treatment of HER2-positive tumors can be achieved. Clinically, its use should be combined with HER2 test results to ensure patient suitability, and treatment should be carried out under the guidance of professional doctors to achieve optimal efficacy and control safety risks.

Keyword tags: vedicitumab, ADCdrugs, HER2positive tumors, targeted therapy, precise killing

Reference materials:https://en.wikipedia.org/wiki/Disitamab_vedotin